Bionas signs service contract with Solvay Pharmaceuticals

3 October 2007

Bionas GmbH, a specialist in in-vitro profiling of cellular metabolic activity, has signed a service contract with German firm Solvay Pharmaceuticals GmbH. The contract covers the metabolic profiling of several drug candidates identified in the context of Solvay's obesity research program.

Solvay has selected the Bionas 2500 analysing system because it allows monitoring of both acute and chronic effects of drug candidates in different cell types thanks to a proprietary perfusion system. Besides the long-term observation of cells under close to in vivo conditions, the observation of regeneration effects is also possible.

"The Bionas instrument is a valuable tool for compound ranking and helps us select the most promising compounds for further development," says Dr. Michael Firnges at Solvay Pharmaceuticals GmbH.

The Bionas system is a bench-top instrument that allows the simultaneous, label-free and high-content analysis of three metabolic parameters, such as acidification, oxygen consumption and adhesion of living cells. The Bionas instrument has been also selected by Solvay Pharmaceuticals Research Laboratories (Weesp, Netherlands) for target validation studies.

To top

Save this page on del.icio.us